Business Context and Reporting Period
This Form 8-K was filed by AIT Therapeutics, Inc. on February 6, 2018, reporting events occurring on January 30 and 31, 2018. The company is an emerging growth company focused on developing novel drug therapies, specifically a Nitric Oxide (NO) delivery system designated as a medical device by the FDA.
Key Financial Metrics and Agreements
The filing details a material definitive agreement rather than periodic financial results. Key financial terms of the NitricGen License agreement include:
- Upfront and Milestone Payments: An aggregate of $2 million payable to NitricGen, Inc., primarily tied to regulatory milestones.
- Royalties: Low-single-digit percentage on net sales of the delivery system containing the eNOGenerator.
- Equity Consideration: Issuance of options to purchase 100,000 shares of common stock at an exercise price of $6.90.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes and Operational Updates
On January 31, 2018, the company acquired a global, exclusive, transferable license to the eNOGenerator and associated intellectual property from NitricGen, Inc. This technology allows for on-demand generation of NO at concentrations ranging from 1 ppm to 400 ppm, eliminating the need for high-pressure cylinders. Additionally, as of February 5, 2018, the company reported the safe completion of 91 treatments (30 minutes each) over a 21-day period for a patient with mycobacterium abscessus under compassionate use at the National Institutes of Health.
Outlook, Risks, and Contingencies
Management expects the licensed technology to target all conditions requiring NO at any concentration and potentially enable home use. The company anticipates the compassionate use patient will continue treatments during the first quarter of 2018. Significant risks include the unproven nature of the drug discovery approach, dependence on third parties for development and distribution, difficulties in patient enrollment, and the early-stage status of all product candidates. The company disclaims any obligation to update forward-looking statements.
Investor Verification Checklist
- Verify the specific regulatory milestones triggering the $2 million payment schedule.
- Confirm the exact royalty percentage defined as "low-single digits" in the full license agreement.
- Monitor the clinical outcomes of the compassionate use case at the NIH.
- Assess the dilution impact of the 100,000 stock options granted to NitricGen.
- Review the company's cash position to ensure sufficiency for upcoming milestone payments and operations.